Impetigo News and Research

RSS
Impetigo (sometimes impetaigo) is a superficial bacterial skin infection most common among pre-school children. People who play close contact sports such as rugby, American football and wrestling are also susceptible, regardless of age. Impetigo is not as common in adults. It is also highly contagious. The name derives from the Latin ''impetere'' ("assail"). It is also known as school sores.
NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

Alcon concludes 'proof of concept' clinical trial of NovaBay's Aganocide for viral conjunctivitis treatment

Alcon concludes 'proof of concept' clinical trial of NovaBay's Aganocide for viral conjunctivitis treatment

NovaBay to present two poster presentations at IDSA Annual Meeting

NovaBay to present two poster presentations at IDSA Annual Meeting

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

Researchers develop infected tissue model for Aganocide compounds

Researchers develop infected tissue model for Aganocide compounds

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

NovaBay second-quarter net loss increases to $1.2 million

NovaBay second-quarter net loss increases to $1.2 million

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

Ten prevention tips to stay safe from infection and illness during summer camp

Ten prevention tips to stay safe from infection and illness during summer camp

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

NovaBay first-quarter net loss increases to $1.6 million

NovaBay first-quarter net loss increases to $1.6 million

NovaBay to present data on Aganocide compounds at ARVO annual meeting

NovaBay to present data on Aganocide compounds at ARVO annual meeting

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

Galderma S.A. offers $3.75 million to NovaBay Pharmaceuticals

Galderma S.A. offers $3.75 million to NovaBay Pharmaceuticals

Alcon increases its financial support for NovaBay Pharmaceuticals' research and development efforts

Alcon increases its financial support for NovaBay Pharmaceuticals' research and development efforts

Positive results from DermaGen's Phase I/IIa AMP study of atopic dermatitis

Positive results from DermaGen's Phase I/IIa AMP study of atopic dermatitis

NovaBay Pharmaceuticals' Aganocide compounds demonstrate potent antifungal activity against onychomycosis

NovaBay Pharmaceuticals' Aganocide compounds demonstrate potent antifungal activity against onychomycosis

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria